Meta description: Spiro Medical raises $67 million in Series A funding to expand its neuromodulation technology for severe asthma and prepare for regulatory approval.
Spiro Medical has closed a $67 million Series A funding round to accelerate development of its drug-free neuromodulation therapy for asthma. The capital will support device innovation, clinical trials, and regulatory submissions. The announcement matters for investors in medtech, founders seeking growth strategies, and healthcare professionals tracking next-generation respiratory care technologies.
Who invested in this round?
The Series A was led by Andera Partners from Paris. Other key investors include Omega Funds, Sherpa Healthcare Partners, HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc. Ltd UK. The syndicate spans North America, Europe, and Asia. This geographic mix supports global market entry plans and diversified regulatory strategies.
The capital injection strengthens Spiro Medical’s ability to complete clinical work needed for U.S. Food and Drug Administration approvals. It also positions the company to pursue European CE marking, which could offer earlier revenue potential.
What does this funding mean for market growth?
Asthma treatment is a substantial market. Global spending reached an estimated $28.28 billion in 2024 and is projected to exceed $35.93 billion by 2034. Broader asthma therapeutics could reach $51.03 billion over the same period. North America accounted for 51% of spending in 2024, providing a mature environment for launch and reimbursement.
Market drivers include increased asthma prevalence linked to air quality challenges and the need for safer options for younger patients. In the U.S., around 4.9 million children under 18 have been diagnosed with asthma. This underscores the potential impact of a non-pharmaceutical device solution.
How is the technology positioned in respiratory care?
Spiro Medical is developing the first pulmonary neuromodulation system dedicated to asthma treatment. The device applies mild electrical pulses to influence airway nerve activity. This aims to reduce symptoms without the need for inhalers or systemic medication.
Conventional treatments typically rely on bronchodilators, corticosteroids, and biologic therapies. While effective for many, they require lifelong management and can have side effects. By targeting the underlying nerve function, Spiro’s approach addresses root causes rather than symptom control alone.
The company intends to expand its platform to chronic cough and COPD, creating multiple revenue channels from a single technology line. Intellectual property and human data already available provide an advantage against potential future competitors.
Frequently Asked Questions
- How much did Spiro Medical raise?
The company raised $67 million in Series A funding. - Who are the major investors?
Lead investor Andera Partners with participation from Omega Funds, Sherpa Healthcare Partners, HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc. Ltd UK. - What will the funds be used for?
Developing new systems, conducting clinical trials, and pursuing regulatory approvals in the U.S. and Europe. - What is the target market?
Severe asthma patients, with growth plans into chronic cough and COPD segments. - When could the device reach the market?
Regulatory timelines for new devices are typically three to five years for FDA clearance. CE marking may allow earlier European entry.
Key takeaways
This funding round establishes Spiro Medical as a high-potential entrant in respiratory medtech. Strategic investor participation, global reach, and a differentiated technology targeting a multi-billion dollar market create strong momentum. For investors, the deal highlights opportunities in non-pharmaceutical chronic disease management. For founders, it demonstrates the benefit of securing international syndicates for cross-border expansion plans.
Disclaimer
This report is for informational purposes only and should not be considered financial advice. Readers should conduct their own due diligence before making investment decisions.